

National Stock Exchange of India

Circular

Department: Listing	
Download Ref No: NSE/CML/66474	Date: February 03, 2025
Circular Ref. No: 0222/2025	

To All Members,

Sub: Suspension of trading in equity shares – Parenteral Drugs (India) Limited (PDPL)

Parenteral Drugs (India) Limited vide its announcement dated January 24, 2025, informed the Exchange regarding approval of the resolution plan by Hon'ble NCLT, Mumbai bench.

As per the successful Resolution Plan, existing equity shares of the Company shall stand delisted without any cost or liability. Further, in terms of the Resolution Plan, the entire existing paid-up equity share capital of the Company will stand extinguished with Nil payment.

Trading in the equity shares of Parenteral Drugs (India) Limited is currently suspended w.e.f. August 22, 2023, pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020. Further, trading in the equity shares of the Company shall continue to remain suspended pursuant to the Resolution Plan approved by the NCLT order dated January 16, 2025.

**For and on behalf of
National Stock Exchange of India Limited**

**Kavish Surana
Manager**